The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEden Regulatory News (EDEN)

Share Price Information for Eden (EDEN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.275
Bid: 4.15
Ask: 4.40
Change: -0.025 (-0.58%)
Spread: 0.25 (6.024%)
Open: 4.30
High: 4.325
Low: 4.275
Prev. Close: 4.30
EDEN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small Cap Virtual Investor Conference

28 Nov 2023 07:00

RNS Number : 8894U
Eden Research plc
28 November 2023
 

 

Eden Research to Present at the Small Cap Virtual Investor Conference November 30, 2023

 

Company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at VirtualInvestorConferences.com

 

Didcot, Oxfordshire, November 28, 2023 -- Eden Research plc (AIM:EDEN | OTCQB: EDNSF), based in Oxfordshire, UK, focused on sustainable biopesticides and plastic-free formulation technology for use in global crop protection, animal health and consumer products industries, today announced that Sean Smith, Chief Executive Officer, will present live at the Small Cap Virtual Investor Conference, hosted by VirtualInvestorConferences.com, on November 30, 2023.

 

DATE: November 30, 2023

TIME: 09:30 - 10:00 ET | 14:30 - 15:00 GMT

LINK: https://bit.ly/46MMy8s

 

This will be a live, interactive online event where investors are invited to ask the company

questions in real-time. If attendees are not able to join the event live on the day of the

conference, an archived webcast will also be made available after the event.

 

It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates. 

 

Learn more about the event at www.virtualinvestorconferences.com.

 

Recent Company Highlights

 

? Launch of Ecovelex, Eden's third flagship sustainable crop protection product, in collaboration with Corteva

? Successful fundraise of £9.9 (c. $12.5) million to accelerate the company's growth

? Various regulatory approvals across key regions including the US and Central Europe

? Recent regulatory approvals have converted to 55% rise in product sales in FY 2022.

? Over 140 field trials run in 2023 with potential distribution partners for an insecticide, Eden's next crop protection product

 

###

 

About Eden Research plc

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

 

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market:

 

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

 

Cedroz? is a bionematicide that targets free living nematodes which are parasitic worms that affect a wide range of high-value fruit and vegetable crops globally. Cedroz is registered for sale on two continents and Eden's commercial collaborator, Eastman Chemical, is pursuing registration and commercialisation of this important new product in numerous countries globally.

 

Eden's Sustaine® encapsulation technology is used to harness the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with both natural and synthetic compounds to enhance their performance and ease-of-use. Sustaine microcapsules are naturally-derived, plastic-free, biodegradable micro-spheres derived from yeast. It is one of the only viable, proven and immediately registerable solutions to the microplastics problem in formulations requiring encapsulation.

 

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN. It was awarded the London Stock Exchange Green Economy Mark in January 2021, which recognises London-listed companies that derive over 50% of their total annual revenue from products and services that contribute to the global green economy. Eden derives 100% of its total annual revenues from sustainable products and services.

 

For more information about Eden, please visit: www.edenresearch.com.

 

About Virtual Investor Conferences®

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

 

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

 

 

CONTACTS:

 

Hawthorn Advisors (PR advisor to Eden Research)

eden@hawthornadvisors.com

+44 (0)20 3745 4960

 

Virtual Investor Conferences

John M. Viglotti

SVP Corporate Services, Investor Access

OTC Markets Group

(212) 220-2221

johnv@otcmarkets.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFIFSELDLTFIV
Date   Source Headline
13th Jul 201810:23 amRNSDirector/PDMR Shareholding
21st Jun 20184:44 pmRNSResult of AGM
21st Jun 20187:00 amRNSAGM Statement
19th Jun 20187:00 amRNSDirector/PDMR Shareholding
14th Jun 20187:00 amRNSRegulatory Progress Update
30th May 20182:30 pmRNSPosting of Annual Report & Notice of AGM
10th May 20185:04 pmRNSDirector/PDMR Shareholding
8th May 20187:00 amRNSExercise of Options
20th Mar 20187:00 amRNSPreliminary results
11th Jan 20187:00 amRNSYear-end Trading Statement
12th Dec 20177:00 amRNSRegulatory Progress Update
29th Sep 201711:15 amRNSHalf-year Report - Replacement
29th Sep 20177:30 amRNSAdoption of New LTIP and Grant of Awards
29th Sep 20177:01 amRNSBoard Changes
29th Sep 20177:00 amRNSHalf-year Report
25th Sep 20177:00 amRNSApproval of MevaloneT in Portugal
1st Sep 20177:00 amRNSNotice of Results
30th Jun 20175:14 pmRNSHolding(s) in Company
30th Jun 201712:29 pmRNSResult of AGM
30th Jun 20177:43 amRNSAGM Statement
30th Jun 20177:39 amRNSCompletion of Placing & Subscription
30th Jun 20177:00 amRNSSipcam agreements, investment and proposed placing
29th Jun 20179:43 amRNSNew terms agreed with UMMS
5th Jun 20173:14 pmRNSPosting of Annual Report & Notice of AGM
22nd May 20177:00 amRNSFinal Results
11th May 20179:00 amRNSEden Research on BBC Radio 4's You & Yours
29th Mar 20177:00 amRNSExtension of patent protection in Greece
8th Mar 20172:40 pmRNSVoting Rights, Warrants and Options Outstanding
23rd Jan 20172:00 pmRNSPrice Monitoring Extension
23rd Jan 20177:00 amRNSFungicide product approved for sale in France
21st Dec 20167:01 amRNSTrading update
21st Dec 20167:00 amRNSEastman commercialisation agreement for nematicide
27th Sep 20167:00 amRNSHalf-year Report
28th Jun 201612:28 pmRNSResult of AGM
28th Jun 20167:00 amRNSAGM Statement
15th Jun 20167:00 amRNSLabel extensions for 3AEY in Spain and Greece
7th Jun 20167:00 amRNSPosting of Annual Report & Notice of AGM
26th May 20163:36 pmRNSDirector/PDMR Shareholding
24th May 20167:00 amRNSFinal Results
11th Apr 20169:31 amRNSHolding(s) in Company
30th Mar 20167:00 amRNSPlacing to raise £2.6m
22nd Feb 20167:00 amRNSApproval of 3AEY in Spain
11th Feb 20167:00 amRNSApproval of 3AEY in Italy
10th Feb 20167:00 amRNSFirst shipment of MevaloneT (3AEY) to Greece
21st Jan 20167:00 amRNSExercise of options
14th Jan 20167:00 amRNSFurther progress with EU product approvals
16th Nov 20157:00 amRNSKenya approval & first commercial-scale order
26th Oct 20157:00 amRNSAppointment of Nominated Adviser and Broker
24th Sep 20157:00 amRNSCollaboration and Licence Agreement Signed
15th Sep 20157:00 amRNSHalf Yearly Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.